The European Commision approves La Jolla Pharmaceutical Company’s (NASDAQ:LJPC) GIAPREZA (angiotensin II) for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies.
Angiotensin is a peptide hormone that stabilizes blood pressure (BP) in hypotensive patients via vasocontriction which increases BP. It also helps kidneys balance body fluids and electrolytes.
Shares up 5% premarket on light volume.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.